Minerva Neurosciences | NERV - Cost Of Sales


Minerva Neurosciences reported 386K in Cost of Sales for its fiscal quarter ending in June of 2024.





Cost Of Sales Change Date
Acadia Pharmaceuticals USD 24.79M 1.43M Mar/2026
Adma Biologics USD 33.74M 16.65M Mar/2026
ALKERMES USD 73.25M 27.04M Mar/2026
AstraZeneca USD -204M 3.48B Mar/2026
BioCryst Pharmaceuticals USD 9.52M 7.34M Dec/2025
Bristol-Myers Squibb USD 3.86B 1.07B Mar/2026
Cipla INR 29.71B 3.4B Jun/2026
Clal Biotechnology ILS 16.49M 2.64M Jun/2022
Compugen USD 1.82M 1.71M Mar/2026
CSL USD 3.87B 2.08B Dec/2025
Eli Lilly USD 3.58B 205M Mar/2026
GlaxoSmithKline GBP 1.88B 736M Mar/2026
Grifols EUR 1.51B 184.45M Dec/2025
Halozyme Therapeutics USD 108.75M 6.6M Mar/2026
Ionis Pharmaceuticals USD 3M 5M Mar/2026
J&J USD 8B 67M Jun/2026
Merck USD 2.94B 380M Mar/2026
Minerva Neurosciences 386K 31K Jun/2024
Neurocrine Biosciences USD 13.8M 3.8M Mar/2026
Novartis USD 3.46B 83M Mar/2026
Novavax USD 22.1M 608K Dec/2025
Pfizer USD 4.59B 1.7B Mar/2026
Roche Holding CHF 7.85B 630M Jun/2026
Sanofi EUR 3.67B 621M Mar/2026
Takeda JPY 560.54B 159.39B Mar/2026
Vanda Pharmaceuticals USD 198.77M 151.12M Dec/2024